Each participant underwent comprehensive physical and ocular examinations. Fasting blood samples were used to measure hemoglobin A1c (HbA1c), SUA (or UA), serum creatinine, total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and C-reactive protein. Clean midstream urine samples were used to quantify urine microalbumin. Hyperuricemia was defined as an SUA level >420 µmol/L in men and >360 µmol/L in women. Height, weight, waist, hip, systolic blood pressure (SBP), and diastolic blood pressure (DBP) were also measured using standardized protocols. Body mass index (BMI = weight [kg]/height [m2]) and mean arterial pressure ([SBP + 2 × DBP]/3) were calculated. In-person interviews by trained interviewers were performed to collect information on detailed ophthalmic and systemic medical history by using a standard questionnaire.
The ophthalmic examinations included slit-lamp biomicroscopy, visual acuity, IOP, refraction, ocular biometry measurements, optical coherence tomography (OCT), and OCTA. Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) LogMAR E chart (Precision Vision, Villa Park, IL, USA). Refractive error was measured by an automated refractometer (KR8800; Topcon, Tokyo, Japan), and IOP was measured by a noncontact IOP meter (Topcon CT-80A; Topcon). Central corneal thickness, lens thickness, axial length, and anterior chamber depth were measured by an optical low-coherence reflectometer (Lenstar LS900; Haag-Streit AG, Koeniz, Switzerland). After pupil dilatation, two 45° fundus color photographs were obtained using a digital fundus camera (Canon CR-2, Tokyo, Japan) centered on the macula and the optic disc, respectively.